A COVID‑19 vaccine is designed to induce immunity against SARS-CoV-2, the virus responsible for coronavirus disease 2019. COVID-19 vaccines help reduce the risk of severe illness, hospitalization and
A conceptual diagram showing three vaccine types for forming SARS‑CoV‑2 proteins to prompt an immune response: (1) RNA vaccine; (2) subunit vaccine; (3) viral vector vaccine
Vaccine platforms that are being employed for SARS-CoV-2. Whole-virus vaccines include both attenuated and inactivated forms of the virus. Protein and peptide subunit vaccines are usually combined with an adjuvant to enhance immunogenicity. The main emphasis in SARS-CoV-2 vaccine development has been on using the whole spike protein in its trimeric form, or its components, such as the RBD region. Multiple non-replicating viral vector vaccines have been developed, particularly focused on
Diagram of the operation of an RNA vaccine. Messenger RNA contained in the vaccine enters cells and is translated into viral proteins, which trigger an immune response.
Vial of Novavax vaccine from clinical trials at Thackray Museum of Medicine
The global COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2, began with an outbreak in Wuhan, China, in December 2019. It spread to other parts of Asia and then worldwide i
COVID-19 vaccine
…reduce the risk of severe illness, hospitalization and death from the virus. COVID‑19 vaccines were developed at an unprecedented pace to tackle the COVID-19 pandemic, with the first clinical trials beginning in March 2020. Before approval, vaccines underwent the standard three phases of clinical trials, although…
Medical professionals treating a COVID-19 patient in critical condition in an intensive care unit in São Paulo in May 2020
Chinese medics in Huanggang, Hubei, in 2020
Gravediggers bury the body of a man suspected of having died of COVID-19 in the cemetery of Vila Alpina in eastern São Paulo, 3 April 2020.
The deceased in a refrigerated "mobile morgue" outside a hospital in Hackensack, New Jersey, US, in April 2020